Tyra Bioscience (TYRA)
NASDAQ:TYRA
TYRA Stock Chart & Stats
$36.32
-$0.12(-0.75%)
At close: 4:00 PM EST
$36.32
-$0.12(-0.75%)
Day’s Range― - ―
52-Week Range$6.42 - $39.15
Previous CloseN/A
Volume80.11K
Average Volume (3M)370.94K
Market Cap
$1.98B
Enterprise Value$1.90B
Total Cash (Recent Filing)$256.00M
Total Debt (Recent Filing)$5.81M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Apr 30, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding53,867,115
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.99K
Enterprise Value/Ebitda-15.91
Forecast
1Y Price Target
$50.71Price Target Upside39.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data CatalystsA planned pivotal-intent study in low-grade upper tract urothelial carcinoma and upcoming Phase II readouts in related bladder indications could deliver efficacy signals that lift program valuation and investor interest.
Commercial Strategy And Market OpportunityConcentrating development on non-muscle-invasive bladder cancer, low-grade upper tract urothelial carcinoma, and achondroplasia leverages a focused three-by-three strategy to maximize return on invested capital and commercial potential across multiple indications.
Drug Design And SelectivityDabogratinib's FGFR3-selective design could allow higher on-target dosing with fewer off-target toxicities, supporting the potential for stronger efficacy and improved tolerability versus older pan-FGFR inhibitors.
Bears Say
Class Tolerability And Adoption RiskSignificant tolerability problems seen with earlier FGFR therapies, including frequent dose reductions and disruptive side effects, highlight the risk that safety issues could limit adoption or require dose compromises.
Clinical Evidence UncertaintyCompletion of enrollment for an early-stage metastatic study without published results creates uncertainty about clinical activity in advanced disease and increases overall program risk.
Financial Runway And Funding RiskOngoing operating losses alongside rising research spending increase reliance on positive clinical readouts to justify valuation and secure additional financing.
Tyra Bioscience News
TYRA FAQ
What was Tyra Bioscience’s price range in the past 12 months?
Tyra Bioscience lowest stock price was $6.42 and its highest was $39.15 in the past 12 months.
What is Tyra Bioscience’s market cap?
Tyra Bioscience’s market cap is $1.98B.
When is Tyra Bioscience’s upcoming earnings report date?
Tyra Bioscience’s upcoming earnings report date is Apr 30, 2026 which is in 35 days.
How were Tyra Bioscience’s earnings last quarter?
Tyra Bioscience released its earnings results on Mar 02, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.532 by -$0.038.
Is Tyra Bioscience overvalued?
According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued.
Does Tyra Bioscience pay dividends?
Tyra Bioscience does not currently pay dividends.
What is Tyra Bioscience’s EPS estimate?
Tyra Bioscience’s EPS estimate is -0.59.
How many shares outstanding does Tyra Bioscience have?
Tyra Bioscience has 53,867,115 shares outstanding.
What happened to Tyra Bioscience’s price movement after its last earnings report?
Tyra Bioscience reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.532. Following the earnings report the stock price went up 1.507%.
Which hedge fund is a major shareholder of Tyra Bioscience?
Currently, no hedge funds are holding shares in TYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tyra Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.71 (39.62% Upside)
$50.71 (39.62% Upside)
Hedge Fund Trend
Increased
By 951.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 9.3%
Last 30 Days ▲ 9.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.61%
12-Months-Change
Fundamentals
Return on Equity
-34.75%
Trailing 12-Months
Asset Growth
-20.69%
Trailing 12-Months
Company Description
Tyra Bioscience
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
TYRA Stock 12 Month Forecast
Average Price Target
$50.71
▲(39.62% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Palvella Therapeutics
―
Gossamer Bio
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―